What aripiprazole (Abilify) dose should be used to transition a hospitalized patient on lithium carbonate 300 mg twice daily who has developed acute kidney injury to maintain mood stability?

Transitioning from Lithium to Aripiprazole in Acute Kidney Injury

In a hospitalized patient on lithium 300 mg BID who develops acute kidney injury, initiate aripiprazole at 10–15 mg daily as a single dose to maintain mood stability, while immediately discontinuing lithium. 1, 2

Immediate Lithium Management in AKI

• Discontinue lithium immediately when AKI is identified, as lithium is explicitly listed among medications that must be stopped in patients with serious intercurrent illness and GFR <60 mL/min/1.73 m². 1
• Lithium requires renal excretion and has a narrow therapeutic window, making it particularly dangerous in AKI where drug clearance is unpredictable and toxic accumulation occurs rapidly. 1, 3
• The patient is at high risk for lithium toxicity given the AKI, which can manifest as neurotoxicity (tremors, confusion, seizures) and further nephrotoxicity, creating a dangerous cycle. 4, 5, 6

Aripiprazole Dosing Strategy

Start aripiprazole at 10–15 mg once daily for several evidence-based reasons:

• Aripiprazole pharmacokinetics are not meaningfully altered by renal impairment, as renal clearance is negligible (0.04 mL/h/kg) and the drug is primarily metabolized hepatically via CYP2D6 and CYP3A4. 7
• No dose adjustment is required in renal impairment, including severe renal dysfunction (creatinine clearance <30 mL/min). 7
• The standard therapeutic range for mood stabilization is 10–30 mg daily, with 10–15 mg representing a conservative starting point that balances efficacy with tolerability during the acute hospitalization. 7

Rationale for This Transition Approach

The lithium dose of 300 mg BID (600 mg total daily) represents a moderate therapeutic dose, suggesting the patient requires meaningful mood stabilization. The transition strategy prioritizes:

• Immediate discontinuation of the nephrotoxic agent (lithium) to prevent further renal injury and avoid toxic accumulation. 1, 2
• Prompt initiation of a renally-safe alternative (aripiprazole) to prevent mood destabilization during hospitalization. 7
• Conservative dosing given the acute medical illness, recognizing that AKI can alter hepatic drug metabolism and protein binding even for non-renally cleared medications. 3

Critical Monitoring Requirements

• Check serum creatinine and eGFR at least every 48 hours during the acute AKI phase to track renal recovery. 2
• Monitor for extrapyramidal symptoms and akathisia, which are the primary dose-limiting side effects of aripiprazole, particularly during the first week. 7
• Assess mood stability daily during hospitalization, as the transition from lithium to aripiprazole may require 5–7 days to achieve steady-state therapeutic levels. 7
• Measure lithium levels if neurotoxicity symptoms (tremor, confusion, ataxia) emerge, as residual lithium may persist for several days post-discontinuation in AKI. 1, 5

Common Pitfalls to Avoid

Do not attempt to continue lithium with dose reduction in the setting of AKI, as the unpredictable pharmacokinetics and narrow therapeutic window make safe dosing impossible. 1, 3

Do not delay aripiprazole initiation waiting for complete renal recovery, as mood destabilization during hospitalization increases length of stay and complicates medical management. 7

Do not combine multiple antipsychotics during this transition (e.g., adding quetiapine for sleep), as polypharmacy with antipsychotics in the setting of organic illness (AKI) substantially increases the risk of neuroleptic malignant syndrome. 4

Do not use aripiprazole doses >15 mg initially in the acute hospitalization setting, as higher doses do not provide faster mood stabilization but do increase the risk of akathisia and other adverse effects. 7

Dose Titration After AKI Resolution

• Once renal function stabilizes (creatinine no longer rising, urine output adequate), assess mood stability at the 10–15 mg dose for at least 1–2 weeks before considering titration. 2, 7
• If inadequate response, increase aripiprazole by 5 mg increments every 1–2 weeks up to a maximum of 30 mg daily, which represents the upper limit for mood stabilization. 7
• Do not restart lithium until renal function has fully recovered to baseline and remains stable for at least 2–4 weeks, with close monitoring of lithium levels and renal function if reintroduction is considered. 1, 2